Based on the provided paper content, here are the answers to the questions:

"""
Question: 1101

Evidence: This is the first study that uses NGS to detect the presence of PR and Gag DMRs in treatment-naive Mexican PLWH. The present study reports the detection by NGS of drug resistant mutations in the Gag polyprotein and protease gene associated with protease inhibitor resistance in treatment-naive Mexican PLWH.

Rationale: The paper explicitly states that, to the authors' knowledge, this is the first study using NGS to detect DRMs in the protease gene and Gag polyprotein in ART-naive Mexican PLWH, indicating the data is previously unpublished.

Answer: Yes
"""

"""
Question: 1102

Evidence: HIV Gag and Protease sequences were obtained by NGS. Sequences were deposited at the Sequence Read Archive under BioProject PRJNA823730.

Rationale: The paper describes obtaining HIV Gag and Protease sequences via NGS and depositing them in a public database, confirming it reports HIV sequences.

Answer: Yes
"""

"""
Question: 1103

Evidence: NA

Rationale: The paper describes a cross-sectional study of treatment-naive individuals and does not mention any in vitro passage experiments.

Answer: No
"""

"""
Question: 1104

Evidence: NA

Rationale: The paper focuses on genotypic resistance testing using NGS and does not report any in vitro antiretroviral susceptibility data.

Answer: No
"""

"""
Question: 2101

Evidence: Sequences were deposited at the Sequence Read Archive under BioProject PRJNA823730.

Rationale: The paper confirms that sequences were deposited in a public database (Sequence Read Archive), which uses accession numbers.

Answer: Yes
"""

"""
Question: 2102

Evidence: Sequences were deposited at the Sequence Read Archive under BioProject PRJNA823730.

Rationale: The deposited sequences are from the study participants (treatment-naive Mexican PLWH), not laboratory HIV isolates.

Answer: Yes
"""

"""
Question: 2103

Evidence: Sequences were deposited at the Sequence Read Archive under BioProject PRJNA823730.

Rationale: The paper provides the BioProject accession number (PRJNA823730) but does not list individual GenBank accession numbers for each sequence.

Answer: PRJNA823730
"""

"""
Question: 2202

Evidence: The distribution of all the identified mutations in Gag and protease are shown in (Additional file 1). We observed 1186 amino acid (aa) changes at 346 positions at full-length Gag, and 175 aa changes in 74 positions throughout the protease gene.

Rationale: The paper describes comprehensive mutation analysis across all sequenced isolates and refers to additional files that likely contain detailed mutation lists.

Answer: Yes
"""

"""
Question: 2301

Evidence: Most sequences clustered with HIV-1 subtype B (97.9%).

Rationale: The paper exclusively studies HIV-1, as evidenced by the subtype analysis.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: Most sequences clustered with HIV-1 subtype B (97.9%). Non-B subtypes were identified in 2 (2.1%) PLWH.

Rationale: The paper explicitly states that 97.9% of sequences were subtype B and 2.1% were non-B subtypes.

Answer: Predominantly subtype B (97.9%), with some non-B subtypes (2.1%)
"""

"""
Question: 2303

Evidence: The coding region of HIV-1 Gag and Protease (HXB2 nucleotides 790 to 2550) was amplified. HIV Gag and Protease sequences were obtained by NGS.

Rationale: The paper clearly states that both Gag and Protease genes were sequenced.

Answer: Gag and Protease
"""

"""
Question: 2304

Evidence: NA

Rationale: The paper specifically states it sequenced Gag and Protease genes, not pol gene sequences.

Answer: No
"""

"""
Question: 2401

Evidence: Treatment-naive adult Mexican PLWH were recruited between 2016 and 2019. The Hospital de Infectología is a public national reference center that provides care to nearly 1,000 PLWH a month.

Rationale: The paper clearly states the study was conducted in Mexico City, Mexico at a national reference hospital.

Answer: Mexico (Mexico City)
"""

"""
Question: 2402

Evidence: Treatment-naive adult Mexican PLWH were recruited between 2016 and 2019.

Rationale: The paper explicitly states the recruitment period when samples were obtained.

Answer: 2016-2019
"""

"""
Question: 2502

Evidence: NA

Rationale: The paper states that NGS was used for sequencing and that Sanger sequencing was not performed as a limitation.

Answer: No
"""

"""
Question: 2503

Evidence: HIV Gag and Protease sequences were obtained by NGS. To our knowledge, NGS has not be used to detect pretreatment drug resistance mutations (DRMs) in the HIV protease (PR) gene and its substrate the Gag polyprotein.

Rationale: The paper repeatedly states that Next Generation Sequencing (NGS) was the method used.

Answer: Yes
"""

"""
Question: 2504

Evidence: NA

Rationale: The paper describes using NGS directly on PCR amplicons without mentioning cloning procedures.

Answer: No
"""

"""
Question: 2505

Evidence: NA

Rationale: The paper does not mention single genome sequencing being performed.

Answer: No
"""

"""
Question: 2506

Evidence: NA

Rationale: The paper does not mention molecular cloning being performed as part of the sequencing process.

Answer: No
"""

"""
Question: 2601

Evidence: For RNA extraction, a 1 mL plasma aliquot was thawed per subject and centrifuged at 14,000 rpm at 4 °C for 2 h to concentrate HIV particles. RNA was extracted using the QIAamp Viral RNA Mini Kit.

Rationale: The paper describes extracting RNA from plasma samples, indicating plasma virus sequencing was performed.

Answer: Yes
"""

"""
Question: 2602

Evidence: NA

Rationale: The paper only describes RNA extraction from plasma and does not mention PBMC processing or DNA extraction.

Answer: No
"""

"""
Question: 2603

Evidence: One hundred PLWH attending a public national reference hospital were included. HIV sequences were assigned predominantly to HIV-1 subtype B (97.9%).

Rationale: The study included 100 participants and successfully sequenced viruses from them, indicating 100 samples underwent plasma virus sequencing.

Answer: 100
"""

"""
Question: 2604

Evidence: NA

Rationale: The paper does not mention PBMC virus sequencing.

Answer: 0
"""

"""
Question: 2605

Evidence: The median HIV viral load was 4.99 [4.39–5.40] log copies/mL. Our cohort was mostly composed of subjects with high plasma viral loads.

Rationale: The paper reports high viral loads in participants, indicating active HIV replication.

Answer: Yes
"""

"""
Question: 2606

Evidence: NA

Rationale: The paper sequenced RNA from plasma virus, not proviral DNA from cells.

Answer: No
"""

"""
Question: 2701

Evidence: Treatment-naive adult Mexican PLWH (over 18 years) were recruited.

Rationale: The paper specifically states participants were adults over 18 years old.

Answer: No
"""

"""
Question: 2702

Evidence: NA

Rationale: The paper describes a cross-sectional observational study, not a clinical trial.

Answer: No
"""

"""
Question: 2703

Evidence: NA

Rationale: The paper describes a cross-sectional observational study, not a clinical trial.

Answer: No
"""

"""
Question: 3101

Evidence: One hundred PLWH attending a public national reference hospital were included. HIV sequences were assigned predominantly to HIV-1 subtype B (97.9%).

Rationale: The paper states that 100 individuals were included in the study and sequences were obtained from them.

Answer: 100
"""

"""
Question: 3102

Evidence: One hundred PLWH attending a public national reference hospital were included. HIV sequences were assigned predominantly to HIV-1 subtype B (97.9%).

Rationale: The paper indicates that all 100 included individuals underwent HIV sequencing.

Answer: Yes
"""

"""
Question: 4101

Evidence: Treatment-naive adult Mexican PLWH were recruited between 2016 and 2019. One Hundred HIV-positive ART-naive adult PLWH (over 18 years) were recruited.

Rationale: The paper explicitly states that all participants were treatment-naive.

Answer: Yes
"""

"""
Question: 4102

Evidence: NA

Rationale: The paper specifically states that only treatment-naive individuals were included.

Answer: No
"""

"""
Question: 4103

Evidence: Treatment-naive adult Mexican PLWH were recruited between 2016 and 2019. One Hundred HIV-positive ART-naive adult PLWH (over 18 years) were recruited.

Rationale: The paper clearly states that only ART-naive individuals were included in the study.

Answer: No
"""

"""
Question: 4104

Evidence: One Hundred HIV-positive ART-naive adult PLWH (over 18 years) were recruited between 2016 and 2019.

Rationale: The paper explicitly states that 100 ART-naive individuals were included.

Answer: 100
"""

"""
Question: 4105

Evidence: One Hundred HIV-positive ART-naive adult PLWH (over 18 years) were recruited.

Rationale: Since all participants were treatment-naive, complete ART history (none) is provided for all individuals.

Answer: Yes
"""

"""
Question: 4201

Evidence: The frequency of DRM in the HIV protease was 7.3% at a detection threshold of 1% and 3.1% at a detection threshold of 20%.

Rationale: The paper reports prevalence of drug resistance mutations in treatment-naive individuals, which constitutes transmitted HIV drug resistance.

Answer: Yes
"""

"""
Question: 4202

Evidence: The frequency of DRM in the HIV protease was 7.3% at a detection threshold of 1% and 3.1% at a detection threshold of 20%.

Rationale: The paper reports prevalence of drug resistance mutations in treatment-naive individuals before ART initiation, which constitutes pretreatment HIV drug resistance.

Answer: Yes
"""

"""
Question: 4301

Evidence: Data on the first-line ART regimen was available for 98 PLWH: 62 (63.3%) initiated with 2 NRTI + 1 NNRTI, 34 (34.7%) with 2 NRTI + 1 PI and 1 (1.0%) with 2 NRTI + 1 INSTI.

Rationale: The paper reports that individuals received NRTIs, NNRTIs, PIs, and INSTIs as part of their first-line regimens.

Answer: NRTIs, NNRTIs, PIs, INSTIs
"""

"""
Question: 4302

Evidence: 1 (1.0%) with 2 NRTI + 1 INSTI.

Rationale: The paper reports that one individual received an integrase inhibitor.

Answer: Yes
"""

"""
Question: 4303

Evidence: 34 (34.7%) with 2 NRTI + 1 PI.

Rationale: The paper reports that 34 individuals received protease inhibitors.

Answer: Yes
"""

"""
Question: 4304

Evidence: Data on the first-line ART regimen was available for 98 PLWH: 62 (63.3%) initiated with 2 NRTI + 1 NNRTI, 34 (34.7%) with 2 NRTI + 1 PI and 1 (1.0%) with 2 NRTI + 1 INSTI.

Rationale: The paper shows that individuals received different ART regimens (NNRTI-based, PI-based, and INSTI-based).

Answer: No
"""

"""
Question: 4305

Evidence: One Hundred HIV-positive ART-naive adult PLWH (over 18 years) were recruited.

Rationale: Since all participants were treatment-naive, they were INSTI-naive at baseline.

Answer: Yes
"""

"""
Question: 4403

Evidence: A total of 12 (12.2%) PLWH switched to second line ART, mainly due to side effects.

Rationale: The paper reports that 12 individuals switched to a second regimen, indicating they received more than one ART regimen.

Answer: 12
"""

"""
Question: 4404

Evidence: NA

Rationale: The paper only mentions switching to second-line ART, not third-line or beyond.

Answer: 0
"""

"""
Question: 4405

Evidence: A total of 12 (12.2%) PLWH switched to second line ART.

Rationale: The paper indicates that only some individuals (12/98) switched regimens, while others remained on their first regimen.

Answer: No
"""

"""
Question: 4406

Evidence: A total of 12 (12.2%) PLWH switched to second line ART.

Rationale: The paper shows that not all individuals received only one ART regimen, as 12 switched to second-line.

Answer: No
"""

"""
Question: 4501

Evidence: ABC-3TC-DTG 1 (1.0%).

Rationale: The paper reports that one individual received dolutegravir (DTG).

Answer: 1
"""

"""
Question: 4502

Evidence: NA

Rationale: The paper does not mention darunavir being used in any of the treatment regimens.

Answer: 0
"""

"""
Question: 5101

Evidence: Major PI resistance mutations were found in 8 (8.3%) of 96 patients at a detection threshold of 1% and 3 (3.1%) at a detection threshold of 20%.

Rationale: The paper reports the number of individuals with major PI resistance mutations.

Answer: 8 at 1% threshold, 3 at 20% threshold
"""

"""
Question: 5102

Evidence: NA

Rationale: The paper focuses on protease and Gag mutations, not INSTI-resistance mutations.

Answer: 0
"""

"""
Question: 5103

Evidence: NA

Rationale: The paper focuses on protease inhibitor resistance mutations, not TDF-resistance mutations.

Answer: 0
"""

"""
Question: 5104

Evidence: NA

Rationale: The paper does not report any INSTI-resistance mutations.

Answer: None reported
"""

"""
Question: 6101

Evidence: NA

Rationale: The paper does not mention any phenotypic susceptibility testing being performed.

Answer: NA
"""

"""
Question: 6102

Evidence: NA

Rationale: The paper does not report any IC50 or IC90 values.

Answer: No
"""

"""
Question: 6103

Evidence: NA

Rationale: The paper does not report any IC50 fold change values.

Answer: No
"""

"""
Question: 6104

Evidence: NA

Rationale: The paper does not describe any phenotypic susceptibility assays being used.

Answer: NA
"""

"""
Question: 6105

Evidence: NA

Rationale: The paper does not mention replication capacity testing.

Answer: No
"""

"""
Question: 6106

Evidence: NA

Rationale: The paper does not mention phenotypic drug susceptibility testing for any specific drugs.

Answer: None reported
"""

"""
Question: 7101

Evidence: NA

Rationale: The paper describes sequencing viruses from clinical samples, not creating site-directed mutants.

Answer: No
"""

"""
Question: 7102

Evidence: NA

Rationale: The paper does not describe any in vitro passage experiments.

Answer: No
"""